An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.
This study is testing an experimental oral medication called NEO212, either alone or with standard treatments, to see how well it works and how safe it is. It aims to help adults with certain types of brain tumors or cancers that have spread to the brain from other parts of the body.
You may be able to join if you are 18 or older, have a confirmed brain tumor or cancer that has spread to the brain, and meet specific health and medication requirements. Your past treatment side effects must also be mostly gone.
Participants will take the NEO212 oral capsule by mouth, and some may also receive standard treatments like immunotherapy or chemotherapy. Doctors will closely monitor your health, side effects, and how your body responds to the medication.
The study is currently recruiting participants at multiple locations in California, United States. Your care team will guide you through the specific site details and schedule.
- 1Tests the new oral medication NEO212 for brain tumors and cancers spread to the brain.
- 2Open to adults 18 and older who meet specific health and prior treatment criteria.
- 3Currently recruiting patients at study locations in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.